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ABSTRACT
Introduction Intracerebral haemorrhage (ICH) can be 
devastating and is a common cause of death and disability 
worldwide. Pre- ICH antiplatelet drug use is associated 
with a 27% relative increase in 1 month case fatality 
compared with patients not using antithrombotic drugs. We 
aim to assess the feasibility of conducting a randomised 
controlled testing the safety and efficacy of desmopressin 
for patients with antiplatelet- associated ICH.
Methods and analysis We aim to include 50 patients 
within 24 hours of spontaneous ICH onset, associated 
with oral antiplatelet drug(s) use in at least the preceding 
7 days. Patients will be randomised (1:1) to receive 
intravenous desmopressin 20 µg in 50 mL sodium chloride 
0.9% infused over 20 min or matching placebo. We will 
mask participants, relatives and outcome assessors 
to treatment allocation. Feasibility outcomes include 
proportion of patients approached being randomised, 
number of patients receiving allocated treatment, rate of 
recruitment and adherence to treatment and follow- up. 
Secondary outcomes include change in ICH volume at 
24 hours; hyponatraemia at 24 hours, length of hospital 
stay, discharge destination, early death less than 28 
days, death or dependency at day 90, death up to day 90, 
serious adverse events (including thromboembolic events) 
up to day 90; disability (Barthel index, day 90), quality of 
life (EuroQol 5D (EQ- 5D), day 90), cognition (telephone 
mini- mental state examination day 90) and health 
economic assessment (EQ- 5D).
Ethics and dissemination The Desmopressin for reversal 
of Antiplatelet drugs in Stroke due to Haemorrhage (DASH) 
trial received ethical approval from the East Midlands—
Nottingham 2 research ethics committee (18/EM/0184). 
The DASH trial is funded by National Institute for Healthand 
Care Research RfPB grant: PB- PG-0816-20011. Trial 
results will be published in a peer reviewed academic 
journal and disseminated through academic conferences 
and through patient stroke support groups. Reporting will 
be in compliance with Consolidated Standards of Reporting 
Trials recommendations.
Trial registration numbers NCT03696121; 
ISRCTN67038373; EudraCT 2018-001904-12.
INTRODUCTION
Haemorrhagic stroke
Spontaneous intracerebral haemorrhage 
(ICH) causes approximately 3 million deaths 
per year worldwide1 and is responsible for 
the loss of 64.5 million disability adjusted life 
years per year.2 Two- thirds of survivors are left 
dependent on others.3 Roughly one- third of 
patients are taking antiplatelet drugs at the 
time of ICH in high- income countries, and 
this proportion has been increasing over 
time.4 Pre- ICH antiplatelet drug use is associ-
ated with a 27% relative increase in 1 month 
case fatality compared with patients not using 
antithrombotic drugs.5 Despite development 
of effective treatments for ischaemic stroke 
(thrombolysis, thrombectomy, aspirin, hemi-
craniectomy) there is no proven effective 
drug treatment for ICH, although blood pres-
sure lowering might improve outcome.6
Haematoma expansion
Outcome after ICH is closely related to 
haematoma growth (expansion) which is 
Strengths and limitations of this study
 ► This is the first randomised controlled trial of des-
mopressin versus placebo for patients taking an-
tiplatelet drugs with spontaneous intracerebral 
haemorrhage (ICH).
 ► Robust methodology developed from large interna-
tional multicentre trials in spontaneous ICH such as 
TICH-2 and PATCH.
 ► Desmopressin and placebo are not identical so the 
person administering the intervention will not be 
masked to treatment allocation.
 ► All outcomes assessors are blinded to treatment al-
location to minimise the risk of bias.
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associated with worse outcome (death and disability).7 
Use of antiplatelet drugs or anticoagulants, time from 
onset of symptoms to baseline imaging, and ICH volume 
on baseline imaging are independent predictors of 
haematoma expansion.8
Platelet transfusion, tranexamic acid and recombinant 
activated factor VII have not been shown to improve 
outcomes after antiplatelet associated ICH, raising the 
need to consider alternatives.9
Desmopressin
Desmopressin is a licensed pro- haemostatic drug that can 
be administered intravenously, subcutaneously, intrana-
sally or orally and is used in a number of inherited bleeding 
conditions to treat or prevent bleeding.10–12 Platelet func-
tion remains inhibited for 5–7 days after stopping anti-
platelet drugs. Desmopressin stimulates release of Von 
Willebrand Factor (VWF) and factor VIII from endothe-
lial Weibel- Palade bodies. VWF is responsible for platelet 
adhesion to collagen and may also bind platelets through 
their glycoprotein IIb/IIIa receptors,13 so increased levels 
of VWF have the potential to compensate for the platelet 
function defect associated with antiplatelet drugs. Desmo-
pressin may also increase the formation of procoagulant 
platelets.14
Desmopressin is recommended for the reversal of anti-
platelet drugs in guidelines from the USA15 but not in UK 
guidelines.16 In a recent meta- analysis evaluating desmo-
pressin for reversal of antiplatelet drugs for patients 
undergoing cardiac surgery, desmopressin was found 
to reduce blood loss, transfusion requirements and the 
need for a further operation due to bleeding.17
There are potential risks with use of desmopressin, 
including tachycardia hypotension, hyponatraemia and 
hyponatraemic seizures. A meta- analysis of 65 surgical 
randomised controlled trials, comparing desmopressin 
to placebo found no significant difference in rates 
of ischaemic stroke, myocardial infarction or venous 
thromboembolism.18
Desmopressin has been tested in ICH in four case 
series where it appears to be safe.19–22 However, the series 
were small, non- randomised and did not have a placebo 
control arm, so it is not possible to make a clear assess-
ment of the benefits and harms of administering desmo-
pressin for these patients. American neurocritical care 
guidelines for the treatment of intracranial haemorrhage 
recommend consideration of 0.4 μg/kg desmopressin for 
treatment of antiplatelet- associated ICH,15 although the 
level of evidence supporting this recommendation was 
recognised as very uncertain.
Searches of  clinicaltrials. gov and WHO Interna-
tional Trials Clinical Registry Platform found no other 
ongoing randomised controlled trials of desmopressin vs 
placebo for reversal of antiplatelet drugs in stroke due to 
haemorrhage.
If it is feasible to recruit patients and to collect robust 
data then we intend to proceed to a definitive trial to test 
efficacy.
Primary objective
To assess the feasibility of randomising, administering 
the intervention and completing follow- up for patients 
treated with desmopressin or placebo to inform a defin-
itive trial.
METHODS AND ANALYSIS
Desmopressin for reversal of Antiplatelet drugs in 
Stroke due to Haemorrhage (DASH) will be a multi-
centre double- blind randomised placebo- controlled, 
parallel group phase II feasibility trial. Participants will be 
enrolled by investigators from emergency departments or 
acute stroke units from 10 hospital sites in the UK. Patient 
flow though the trial is summarised in figure 1.
Inclusion criteria
 ► Adults (≥18 years).
 ► Confirmed ICH on imaging.
 ► Randomised less than 24 hours from onset of symp-
toms (or from when last seen free of stroke symptoms).
 ► Prescribed and thought to be taking a daily oral anti-
platelet drug in the preceding 7 days (cyclo- oxygenase 
inhibitors, phosphodiesterase inhibitors or P2Y12 
inhibitors).
Exclusion criteria
 ► Known secondary causes of ICH (aneurysmal suba-
rachnoid haemorrhage or haemorrhage due to trans-
formation of infarction, thrombolytic drug, venous 
thrombosis, arteriovenous malformation or tumour).
 ► Patients at risk of fluid retention.
 ► Systolic blood pressure less than 90 mm Hg.
 ► Known drug eluting stent in previous 3 months.
 ► Allergy to desmopressin.
 ► Pregnant or breast feeding.
 ► Life- expectancy less than 4 hours or planned for palli-
ative care only.
 ► Glasgow coma scale less than 5.
 ► Modified Rankin scale (mRS) more than 4.
Consent
Patients with capacity to give consent will be approached 
directly. If this is not possible, a relative or close friend 
will be approached for consent, if this is not possible 
then a professional not associated with the trial will 
be approached for proxy consent. Patients will be 
approached again for consent when they regain capacity 
(online supplemental files 1–3; all trial documents are 
available at: http:// dash- 1. ac. uk/ docs/ public. php).
Randomisation
Participants will be randomised centrally using a secure 
internet site in real- time. Treatment allocation will be 
concealed from all staff and patients involved in the trial. 
Randomisation involves minimisation on key prognostic 
risk factors: age (70 years or more); sex (male); time since 
onset (3 hours or more); systolic blood pressure (170 mm 
Hg or more); and presence (or no information on 
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presence or absence) of intraventricular haemorrhage. 
This approach ensures concealment of allocation, mini-
mises differences in key baseline prognostic variables and 
slightly improves statistical power.23 Randomisation will 
allocate a number corresponding to a treatment pack and 
the participant will receive treatment from the allocated 
numbered pack. It was considered not possible to mask/
blind personnel preparing the injection for administra-
tion to the treatment allocation because the ampoules 
of active and placebo injections are different and carry 
the manufacturer’s identifying information. Clinicians, 
patients and outcome assessors (clinical, radiological and 
haematological assessors) will be blinded to treatment 
allocation.
In general, there should be no need to unblind the 
allocated treatment. If some contraindication to desmo-
pressin develops after randomisation, the trial treatment 
should be stopped. Unblinding should be done only in 
those rare cases when the doctor believes that clinical 
management depends importantly on knowledge of 
whether the patient received desmopressin or placebo. 
In those few cases when urgent unblinding is considered 
Figure 1 Study flowchart.
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necessary, the doctor will call an emergency telephone 
number. The caller will then be told whether the patient 
received desmopressin or placebo. The rate of unblinding 
will be monitored and audited.
Intervention
Patients will be randomised to either 20 μg intravenous 
desmopressin (DDAVP, 4 μg/mL 1 mL glass ampoules, 
Ferring Pharmaceuticals) or placebo of intravenous 
sodium chloride 0.9%. Placebo was selected for compar-
ison because at present there are no established haemo-
static therapies for ICH. Either desmopressin 20 μg 
(5×4 μg/mL) will be added to 50 mL sodium chloride 
0.9% and infused over 20 min, or three 2 mL sodium 
chloride 0.9% will be added to 50 mL sodium chloride 
0.9% and infused over 20 min. The investigational medic-
inal product (IMP) will be stored between 2°C and 8°C 
until use. All patients will receive all usual standard care 
including venous thromboembolism prophylaxis with 
intermittent pneumatic compression devices, blood pres-
sure lowering therapy and neurosurgery if appropriate.
We will administer a single dose as the risk of continued 
bleeding and haematoma expansion after ICH is greatest 
in the first few hours. High levels of factor VIII and VWF 
are maintained for 6–8 hours after intravenous infusion 
therefore we believe a repeated dose at 12–24 hours 
would not be indicated. This dose regime (0.4 μg/kg body 
weight administered by intravenous infusion) is recom-
mended in American neurocritical care guidelines for 
the treatment of intracranial haemorrhage,15 although 
the level of evidence supporting this recommendation 
was recognised as very uncertain.
Assessments
Participants’ age, sex, medical history, antiplatelet drug 
use, ICH location, intraventricular haemorrhage and mRS 
will be assessed at baseline by local investigators. Partici-
pants will be reviewed again on day 2, hospital discharge 
and on day 90 to gather information on interventions, 
adverse events, discharge date and discharge destination. 
Data collection forms can be found in online (https:// 
dash- 1. ac. uk/).
At day 90 central assessors trained in the appropriate 
questionnaires and masked to treatment allocation will 
follow- up each patient by telephone. Barthel index, mRS, 
EuroQOL, cognition (mini- mental state examination) 
and serious adverse events will be assessed by telephone.
Brain imaging (CT head) will be undertaken as part 
of routine care before enrolment. A second research CT 
head scan will be performed 24 hours after treatment with 
the IMP to measure parenchymal haematoma volume. 
Haematoma volume will be measured centrally by trained 
assessors masked to treatment allocation using semi- 
automated segmentation. We will assess change in haema-
toma volume at 24 hours, and proportion of patients with 
haematoma expansion, defined as an absolute increase of 
greater than 6 mL or relative growth of greater than 33%.
To assess baseline platelet function, platelets will be 
stimulated with arachidonic acid (which is inhibited 
by aspirin) or adenosine diphosphate (which is inhib-
ited by P2Y12 inhibitors). Platelet cell surface P- selectin 
expression (a measure of platelet activation) will then be 
measured using a standardised assay (Heptinstall; patent 
pending (PTC/GB2008/050169)) to assess retrospec-
tively whether patients were taking antiplatelet drugs, as 
previously described.24 VWF antigen, VWF activity and 
factor VIII (1- stage) will be measured centrally by asses-
sors masked to treatment allocation. Blood samples will 
be drawn into 0.109M citrate and centrifuged at 2500g for 
15 min. Platelet poor plasma will be aspirated and stored 
at −80°C at each site and then transferred to the central 
laboratory at the end of the trial for analysis. These tests 
will be performed for research only and the results will 
not be fed back to the clinical team. Serum sodium will be 
assessed locally 24 hours after administration of the IMP 
and these results will be available to the clinical team.
Outcomes
This is a feasibility trial and the primary outcomes are 
based around feasibility: number of eligible patients 
who receive allocated treatment; rate of eligible patients 
randomised; proportion of eligible patients approached; 
proportion of eligible patients randomised and reasons 
for non- randomisation; adherence to intervention; 
proportion of participants followed up to 90 days and 
reasons for loss to follow- up; proportion of randomised 
participants with full outcome data available, and reasons 
for non- availability.
Secondary outcomes data will be collected to inform 
the design of a definitive trial but will not be statisti-
cally analysed. Secondary outcomes are change in ICH 
volume at 24 hours; hyponatraemia at 24 hours, length of 
hospital stay, discharge destination, early mortality less 
than 28 days, death or dependency at day 90, mortality 
up to day 90, serious adverse events (including thrombo-
embolic events) up to day 90; disability (Barthel index, 
day 90), quality of life (EuroQol, day 90), cognition (tele-
phone mini- mental state examination day 90) and health 
economic assessment (EQ- 5D). Baseline platelet dysfunc-
tion will be measured and correlated with response to 
desmopressin; and change in factor VIII, VWF antigen 
and VWF activity will be assessed 1 hour after administra-
tion of desmopressin.
Adverse events
All adverse events on day 1 (including during infusion) 
and for the 24 hours period post dose will be collected. 
All adverse events will be assessed for seriousness, expect-
edness and causality by adjudicators masked to treatment 
allocation. Serious adverse events will be categorised in 
accordance with the medical dictionary for regulatory 
authorities. As the IMP is administered once and has a 
short half- life, serious adverse events occurring within the 
first 7 days will be assessed for seriousness, expectedness 
and causality. In addition, fatal serious adverse events and 
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safety outcome events (fluid overload, hyponatraemia) 
will be reported until day 90.
Statistical analysis
Data will be analysed by a qualified statistician who is 
blinded to treatment allocation, using a validated soft-
ware package. A statistical analysis plan (SAP) will be 
agreed prior to database lock and release of randomisa-
tion codes. The trial will be reported in accordance with 
Consolidated Standards of Reporting Trials (CONSORT) 
guidelines including the extension to pilot and feasibility 
trials, as appropriate.25 26 This is a feasibility trial and 
the main analysis will be with descriptive statistics only. 
Counts will be summarised using N and %, and contin-
uous variables will be summarised using means and SD 
or medians and IQRs depending on their distribution. 
While some variables will be summarised by treatment 
group, no formal statistical comparisons will be made and 
any analyses will be considered purely exploratory. We will 
assess the feasibility of recruiting, treating and following 
up patients from 10 centres over 1 year. We will estimate 
a recruitment rate, treatment rate and follow- up rate. It 
is likely that a large definitive trial would be feasible if at 
least 50 participants were recruited into this study, that 
compliance with randomised treatment was high and that 
a high proportion of follow- up data were available. Lower 
recruitment would not preclude progression if there was 
some evidence that the barriers to recruitment identi-
fied could be overcome. A decision about feasibility for 
a larger trial will be made in conjunction with the Trial 
Steering Committee (TSC) taking into account recruit-
ment rates, differences between centres and other rele-
vant information.
This is a feasibility trial and as such will have no formal 
assessment of efficacy. The proposed primary efficacy 
outcome in a definitive trial would be death or depen-
dency at day 90, measured using the mRS. Shifts in the 
mRS will be summarised for this trial but no formal confir-
matory statistical analyses will be performed. Similarly, all 
other efficacy variables will be summarised using descrip-
tive statistics. Serious adverse events will be summarised 
using descriptive statistics according to the treatment the 
participant received. Missing data will be reported. The 
investigation of this data and methods implemented to 
address the missing data, if appropriate, will be detailed 
in the SAP.
All available data will be used including overall numbers 
of patients presenting in clinic and screening data (where 
available). Where summaries by treatment group are 
provided, these will be based on an intention to treat 
population that is, according to the treatment the partici-
pant was randomised to, with the exception of safety data. 
A safety population will be defined to summarise the safety 
data in this study where participants will be summarised 
according to the treatment they received irrespective of 
randomisation. Summaries of the number and propor-
tion of participants who would form a per protocol popu-
lation in a larger trial, and reasons for exclusion from a 
per protocol population will be provided to allow future 
planning. No other data will be summarised for this 
population.
Sample size and justification
Since this is a feasibility study with one of the objectives 
being to determine potential recruitment rates, a formal 
sample size calculation is not appropriate. If more than 
50 participants were randomised from 10 centres in a 
12- month period, it is likely that, assuming similar recruit-
ment rates in additional centres, a larger study recruiting 
approximately 1200 participants in around 50 centres 
recruiting for 60 months would be feasible. Depending on 
the final sample size calculation for the definitive study, 
the number of centres and recruitment period could be 
determined using the information from the rates and 
patterns observed in the feasibility study. Information 
about set up times for centres will also better inform 
recruitment projections for a larger study. TICH-2 and 
other studies indicate approximately 25% of all people 
presenting with ICH are taking antiplatelet drugs.27
Patient and public involvement
This study was developed in collaboration with, and is 
supported by Nottingham Stroke Research Partnership 
Group, made up of stroke survivors and carers. Members 
of the group have reviewed the proposed study, and in an 
iterative process, commented on its design and conduct. 
In particular, the group has influenced the approach 
to taking informed consent within the study. In addi-
tion, the proposal was also reviewed by the Research to 
Understand Stroke due to Haemorrhage patient refer-
ence group in Edinburgh (http://www. ed. ac. uk/ clinical- 
brain- sciences/ research/ diagnoses- diseasetargets/ rush/ 
rush- patient- reference- group).
Ethics and dissemination
The trial will be overseen by a TSC. A trial management 
committee based at the Stroke Trials Unit in Nottingham, 
UK will be responsible for day- to- day conduct of the trial. 
An independent Data Monitoring Committee (DMC) will 
review the data at 6 months. Study data will be collected, 
monitored and analysed in Nottingham. The data 
management policy is available at: http:// dash- 1. ac. uk/ 
docs/ public. php. The trial will be run in accordance with 
the principles of good clinical practice and the Declara-
tion of Helsinki. The DASH trial has been granted ethics 
approval by the East Midlands—Nottingham 2 research 
ethics committee (18/EM/0184). The trial has been 
adopted in the UK by the National Institute for Health 
and Care Research.
Trial results will be published in a peer- reviewed 
academic journal. Reporting will be in compliance with 
CONSORT25 26 recommendations. When the study is 
complete summary findings will be posted on the patient 
support group website. Findings will also be presented 
at conferences such as the UK Stroke Forum, Euro-
pean Stroke Conference, World Stroke Congress, British 
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Society for Haematology annual meeting and Interna-
tional Society on Thrombosis and Haemostasis annual 
meeting.
Protocol amendments
Should a protocol amendment be made that requires 
ethics approval, the changes in the protocol will not be 
instituted until the amendment and revised informed 
consent forms and participant information sheets have 
been reviewed and received approval/favourable opinion 
from the research ethics committee and research and 
development departments. The results will be communi-
cated to all principal investigators.
In the initial version of the protocol, which was in 
place from the start of the trial until 30 November 
2019, participants could be recruited if they could be 
randomised less than 12 hours from onset of symptoms 
(or from when last seen free of stroke symptoms). In the 
updated version of the protocol, which came into effect 
on 01 December 2019, participants could be recruited 
if they could be randomised less than 24 hours from 
onset of symptoms (or from when last seen free of stroke 
symptoms).
Confidentiality and access to data
All trial staff and investigators will endeavour to protect 
the rights of the trial’s participants to privacy and 
informed consent, and will adhere to the Data Protec-
tion Act, 2018. The case report forms will only collect the 
minimum required information for the purposes of the 
trial. Case report forms will be held securely, in a locked 
room, or locked cupboard or cabinet. Access to the infor-
mation will be limited to the trial staff and investigators 
and relevant regulatory authorities. Computer held data 
including the trial database will be held securely and 
password protected. All data will be stored on a secure 
dedicated web server. Access will be restricted by user 
identifiers and passwords. Information about the trial 
in the participant’s medical records/hospital notes will 
be treated confidentially in the same way as all other 
confidential medical information. Electronic data will be 
backed up every 24 hours to both local and remote media 
in encrypted format.
Insurance and indemnity
Insurance and indemnity for trial participants and trial 
staff is covered within the National Health Service (NHS) 
Indemnity Arrangements for clinical negligence claims in 
the NHS, issued under cover of HSG (96)48. There are 
no special compensation arrangements, but trial partic-
ipants may have recourse through the NHS complaints 
procedures. The University of Nottingham as research 
Sponsor indemnifies its staff, research participants and 
research protocols with both public liability insurance 
and clinical trials insurance. These policies include provi-
sion for indemnity in the event of a successful litigious 
claim for proven non- negligent harm.
DISCUSSION
This will be the first randomised controlled trial 
comparing desmopressin to placebo for patients with 
ICH who are taking antiplatelet drugs. ICH is a common 
cause of death and disability worldwide. Patients taking 
antiplatelet drugs are more likely to have haematoma 
expansion and to have poorer outcomes than those 
who are not taking an antiplatelet drug. Early treatment 
with drugs to reduce the effect of antiplatelet drugs may 
reduce haematoma expansion. Desmopressin is a prom-
ising drug, which is commonly used in the treatment of 
inherited bleeding disorders and may reduce the effects 
of antiplatelet drugs.
In this trial we aim to determine if it is feasible to 
administer desmopressin within 24 hours to patients with 
ICH taking an antiplatelet drug. One potential barrier 
is that some patients will have delayed presentations to 
hospital. For those that reach hospital within 24 hours, we 
have aimed to make recruitment to the trial streamlined 
by minimising barriers to recruitment. This includes use 
of broad inclusion criteria and using a simple trial design. 
The design of this trial is based on the successful TICH-
227 and PATCH28 multicentre trials. The use of consent 
from a relative, close friend or professional representative 
is essential in this trial because the majority of patients 
will lack capacity.
If it proves feasible to run a trial of desmopressin 
compared with placebo for these patients then we aim 
to proceed to a large efficacy study. This will have an 
important impact on clinical practice. Desmopressin is 
widely available and inexpensive. It has the potential to 
reduce the risk of death and disability for patients with 
ICH who are taking antiplatelet drugs. Desmopressin 
could be rapidly adopted into clinical guidelines if it 
proves to reduce the risk of death or disability for patients 
with ICH.
Trial sponsor contact
Ms Angela Shone, Head of Research Governance, 
Research and Innovation, University of Nottingham, 
East Atrium, Jubilee Conference Centre, Triumph Road, 
Nottingham, NG8 1DH.
Trial Management Group
The Trial Management Group (TMG) will meet regu-
larly, at least every 4 weeks to run the trial. TMG members 
are: Nikola Sprigg—Chief Investigator, Michael Desbor-
ough—Deputy Chief Investigator, Diane Havard—
Senior Clinical Trials Manager, Sharon Ellender—Trial 
Coordinator, Lee Haywood—Programmer, Lisa Wood-
house—Trial statistician and Patricia Robinson—Trial 
Administrator.
Trial Steering Committee
The independent TSC will provide oversight of the trial. It 
will meet (in person or by telephone conference) prior to 
commencement of the trial, and then at regular intervals 
 on N
ovem
ber 17, 2020 by guest. P
rotected by copyright.
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2020-037555 on 10 N
ovem
ber 2020. D
ow
nloaded from
 
7Desborough MJR, et al. BMJ Open 2020;10:e037555. doi:10.1136/bmjopen-2020-037555
Open access
until completion (at least annually). Specific tasks of the 
TSC are:
 ► To approve the trial protocol.
 ► To approve necessary changes to the protocol based 
on considerations of feasibility and practicability.
 ► To receive reports from the Data Safety Monitoring 
Committee.
 ► To resolve problems brought to it by the coordinating 
centre and TMG.
 ► To ensure publication of the trial results.
 ► To advise on whether the main phase of the trial is 
feasible.
TSC members are: Colin Baigent—Chair, Christine 
Knott—patient and public involvement representative, 
Mathew Walters—patient and public involvement repre-
sentative, Angela Shone—Sponsor, Trish Hepburn—
Statistician, Philip Bath—Prof of Stroke Medicine, Rob 
Dineen—Prof of Neuro- radiology, Paul Brennan—
neurosurgeon, Rustam Al- Shahi Salman—Prof of Stroke 
Medicine, Laura Green—Senior Clinical Lecturer in 
Transfusion Research & Innovation, Simon Stanworth—
Associate Professor of Haematology, Tim Coates—Prof 
of Emergency Medicine, Phil Johnson—patient and 
public involvement representative, Emily Toon—Funder 
representative.
The trial coordinator, or where required, a nominated 
designee of the sponsor, shall carry out a site systems 
audit at least yearly and an audit report shall be made to 
the TSC.
Data Monitoring Committee
The independent DMC will receive safety reports every 
6 months, or more frequently if requested and perform 
unblinded reviews of safety data. The DMC will report 
their assessment to the independent chair of the TSC. 
Collaborators, and all others associated with the trial, may 
write through the trial office to the DMC, to draw atten-
tion to any concern they may have about the trial inter-
ventions, or any other relevant issues. There will not be 
an interim analysis. DMC members are: John Bamford—
Chair, Graham Venables—Prof of Neurology, Martin 
Bland—Prof of Statistics.
Participating UK centres
Nottingham University Hospitals NHS Trust; NHS 
Grampian; University College London Hospitals NHS 
Foundation Trust; NHS Lothian; Royal Devon & Exeter 
NHS Foundation Trust; University Hospitals of Leicester 
NHS Trust; University Hospitals of North Midlands NHS 
Trust; Derby Teaching Hospitals NHS Foundation Trust; 
Newcastle Upon Tyne Hospitals NHS Foundation Trust; 
St George’s University Hospitals NHS Foundation Trust.
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PARTICIPANT CONSENT FORM - (Final version 2.0: 26 August 2019) 
 
3 copies: 1 for participant, 1 for the project notes and 1 for the medical notes 
 
       (Form to be printed on local headed paper) 
 
 
 PARTICIPANT CONSENT FORM 
(Final version 2.0: 26 August 2019) 
 
Title of Study: Desmopressin for reversal of Antiplatelet drugs in Stroke due to 
Haemorrhage (DASH) 
 
IRAS Project ID: 233744.     CTA ref : 03057/0070/001-0001  
 
Name of Researcher:         
 
Name of Participant: 
 
1. I confirm that I have read and understand the information sheet version number 2.0: 26 
August 2019 for the above study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, and without my medical care or legal rights being affected. I 
understand that should I withdraw, then the information collected so far cannot be erased 
and that this information may still be used in the project analysis. 
 
3. I understand that relevant sections of my medical notes and data collected in the study 
may be looked at by authorised individuals from the University of Nottingham, the 
research group and regulatory authorities where it is relevant to my taking part in this 
study. I give permission for these individuals to have access to these records and to 
collect, store, analyse and publish information obtained from my participation in this 
study. I understand that my personal details will be kept confidential. 
 
4. I understand and agree that blood samples will be taken for analysis to monitor the 
effects of treatment given in DASH. Samples will be destroyed after analysis. 
 
5. I understand that the information held and maintained by the NHS Digital and other 
central UK NHS bodies may be used to help contact me or provide information about my 
health status. 
 
6. I agree to my GP being informed of my participation in this study and providing 
information about my health status and contact details if needed.  
 
7. I agree to take part in the above study. 
 
 
 
 
______________________ ______________     ____________________ 
Name of Participant   Date          Signature 
 
 
 
________________________ ______________     ____________________ 
Name of Person taking consent Date          Signature 
 
 
 
 
 
Please initial box 
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       Local Letterhead to be added 
 
Participant Information Sheet 
(Final version 2.0: 26 August 2019) 
IRAS Project ID: 233744 
 
Title of Study: Desmopressin for reversal of Antiplatelet drugs in Stroke due to 
Haemorrhage (DASH) 
 
Name of Chief Investigator: Prof Nikola Sprigg 
Local Researcher(s):  xxxxxxxxxxxxxxxxxxxxxxxx  
 
We would like to invite you to take part in our research study. Before you decide we would like you 
to understand why the research is being done and what it would involve for you. One of our team 
will go through the information sheet with you and answer any questions you have. Talk to others 
about the study if you wish. Ask us if there is anything that is not clear, or if you would like more 
information. 
 
What is the purpose of the study? 
When someone has a stroke caused by bleeding into the brain (haemorrhagic stroke) permanent 
brain damage can occur and result in long term disability. There is also a chance that the bleeding 
can increase, which may cause worse disability or be life threatening. This happens in approximately 
20-30% of haemorrhagic stroke patients. Bleeding is worse for patients taking drugs such as aspirin 
or clopidogrel (anti-platelet drugs). 
At present, there is no available treatment that is effective at reducing the bleeding in the brain and 
improving the recovery. New treatments are being developed to treat stroke, but it can be very hard 
to test whether they work in the first few hours because often patients take longer than this to get 
to hospital and have investigations such as brain scanning. Also, some treatments are not suitable 
for all patients. This can make testing new treatments difficult. 
In this trial, we want to test whether it is possible to give a drug (desmopressin) to patients within 
24 hours after a haemorrhagic stroke. Continued or increased bleeding into the brain (so called 
haematoma expansion) is not uncommon in the first hours and days following a haemorrhagic 
stroke and increases the risk of the patient not recovering fully and being left with some disability. 
Stopping the bleeding in the first hours and days after stroke with medications might help patients 
to recover better.  The treatment we are testing is a drug that encourages blood to clot - to stop 
bleeding. We hope that we will be able to show that giving the drug may reduce the chances of 
dying and being left with disability after a haemorrhagic stroke. This drug is not given routinely after 
stroke. 
We aim to assess in this trial what effect desmopressin has on bleeding after a haemorrhagic stroke.  
Desmopressin is a tried and tested drug in other medical conditions that acts quickly to help the 
blood to clot and stop bleeding.   
In order to do a proper comparison, we need to give some people the active drug and some people 
a dummy (placebo) treatment. In this trial, the dummy treatment is salt water.  Half of the patients 
in the trial will receive the drug desmopressin and half will have placebo treatment. 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
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The data will help doctors decide whether blood thickening treatments like desmopressin can be 
used in patients with acute haemorrhagic strokes who are taking anti-platelet drugs to try to 
prevent death and improve recovery. 
Why have I been invited? 
You are being invited to take part because you have had a stroke caused by bleeding into the brain 
– this is called a haemorrhagic stroke. We are inviting 50 participants like you to take part in the 
study. 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you will be given 
this information sheet to keep and be asked to sign a consent form. If you decide to take part you 
are still free to withdraw at any time and without giving a reason. This would not affect your legal 
rights. 
What will happen to me if I take part? 
Your involvement in the study will last for 3 months.  In this study, the treatment (either 
desmopressin or dummy) is given as a drip via a cannula (needle inserted into a vein, usually into 
the back of the hand), which will be given over approximately 20 minutes. 
We select which treatment you receive randomly (like tossing a coin) because this is how most 
clinical trials are carried out. When we don’t know whether a treatment is effective or not we need 
to test it against not getting that treatment (called a control). Using randomisation to put patients 
into treatment groups is the best way to get a true answer as to whether a treatment works or not. 
In this trial, it is important to test whether the drug desmopressin can be given at random in a trial.  
The treatment (either desmopressin or dummy) will be given a drip as soon as possible once you 
have decided you wish to take part in the study. The treatment will be given via a drip over 
approximately 20 minutes. You will not know if you received the drug or the dummy. The treatment 
will be given once, and then the treatment will stop. 
We will take 3 blood samples from the vein in your arm.  One before we start the study treatment to 
look at your blood clotting status, one immediately after and another 24 hours after treatment to 
check the salt levels in your blood stream. Wherever possible these will be taken with any routine 
blood samples your doctor asks for. 
During the next 7 days, a nurse will check your condition looking in particular for signs of side 
effects of the treatment. We will also repeat a brain scan the day after the treatment to assess 
effects of the treatment. The brain scan will last less than 5 minutes but you will need to go to the 
x-ray department for the brain scan, which may take approximately an hour. 
We ask your permission to contact your GP or check with the NHS Information Centre to check on 
your condition three months after your stroke and to confirm your contact details. You will then be 
contacted for a telephone consultation with a member of the research team, this can also be 
conducted by postal questionnaire if you prefer.  This is to check your condition at that time. It will 
involve asking how you are able to move around, about how you feel your life has been affected by 
the stroke and some brief memory tests. In order to make the final evaluation of the study as 
objective as possible, the person who telephones you will not know if you received the active 
treatment or not.  
Other than described here, your treatment will be exactly the same as for all stroke patients. 
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Expenses and payments 
Participants will not be paid to participate in the study. There will be no charge for the trial 
medication. Travel expenses will be offered for any visits incurred as a result of participation. 
 
What are the possible disadvantages and risks of taking part?  
Treatment with any drugs can result in possible side effects and the side effects from desmopressin 
are generally mild. They can include headache, abdominal pain, low blood pressure and dizziness. 
The drug can increase the risk of seizures but this is very rare.  
However, because the treatment works by stopping bleeding there is a chance it can cause an 
increase in blood clot formation. This can occur in the legs (deep vein thrombosis, DVT) or the lungs 
(Pulmonary embolism, PE) and is potentially very serious and maybe even life threatening. If you 
have previously suffered from blood clots in the legs or lungs you may not be able to participate in 
this study.  
In 65 previous studies where desmopressin has been used to reduce bleeding during operations, 
desmopressin was safe. There was no increase in serious side effects, such as blood clots, in the 
patients who were treated with desmopressin. 
Because desmopressin is already routinely used in a number of bleeding conditions, we expect the 
potential benefit of the drug (stopping bleeding in to the brain) to outweigh the low risk of serious 
side effects (such as blood clots). However, we do not know this for certain and will monitor all 
participants closely for side effects. 
You must inform your doctor or member of the research team if you feel you have had a reaction to 
the medication.  
We will take 3 blood samples from the vein in your arm, this can cause mild discomfort/pain and 
slight bruising.  
You will have an extra CT brain scan performed as part of this trial. This is exactly the same as the 
CT scan that you had when you first came to hospital.  The scan itself takes less than 5 minutes and 
does not involve any injections.  The scan uses x-rays, which in large amounts can be harmful, but 
for this extra CT head scan the additional risk to you from the scan has been judged to be extremely 
small and is comparable with the annual risk of dying from an accident in the home. 
You will need to be followed up by the research team for 3 months after starting the study. 
What are the possible benefits of taking part? 
Your participation in this study may reduce the symptoms of your haemorrhagic stroke or improve 
long-term recovery. However, we cannot promise the study will help you, and participation is 
voluntary. The information we get from your involvement may benefit other people who may have a 
stroke in the future. 
 
What happens when the research study stops? 
We aim to treat 50 patients in this study from the UK. When it has finished, we will look at the data 
and decide whether the treatment could be used for more patients with haemorrhagic stroke. We 
may not directly tell you or your relative the results of the study, but they will be published in a 
journal where they can be read. 
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Will my taking part in the study be kept confidential? 
 
We will follow ethical and legal practice and all information about you will be handled in confidence. 
 
If you join the study, we will use information collected from you [and your medical records] during 
the course of the research. This information will be kept strictly confidential, stored in a secure 
and locked office, and on a password protected database at the University of Nottingham.  Under UK 
Data Protection laws the University is the Data Controller (legally responsible for the data security) 
and the Chief Investigator of this study (named above) is the Data Custodian (manages access to 
the data). This means we are responsible for looking after your information and using it properly. 
Your rights to access, change or move your information are limited as we need to manage your 
information in specific ways to comply with certain laws and for the research to be reliable and 
accurate. To safeguard your rights we will use the minimum personally – identifiable information 
possible. 
 
You can find out more about how we use your information and to read our privacy notice at: 
https://www.nottingham.ac.uk/utilities/privacy.aspx.  A hard copy can be made available on request. 
 
The data collected for the study will be looked at and stored by authorised persons from the 
University of Nottingham who are organising the research. They may also be looked at by authorised 
people from regulatory organisations to check that the study is being carried out correctly. All will 
have a duty of confidentiality to you as a research participant and we will do our best to meet this 
duty. 
 
Where possible information about you which leaves the site will have your name and address 
removed and a unique code will be used so that you cannot be recognised from it. However 
sometimes we need to ensure that we can recognise you to link the research data with your medical 
records so in these instances we will need to know your name and date of birth. We will also need 
this information if we need to follow up your medical records as part of the research, where we may 
need to ask the Government services that hold medical information about you (such as NHS Digital, 
the Office for National Statistics, among others) to provide this information to us. By signing the 
consent form you agree to the above. 
 
Your contact information will be kept by the University of Nottingham for 6 months after the end of 
the study so that we are able to contact you about the findings of the study and possible follow-up 
studies (unless you advise us that you do not wish to be contacted). This information will be kept 
separately from the research data collected and only those who need to will have access to it. All 
other data (research data) will be kept securely for 7 years. After this time your data will be 
disposed of securely. During this time all precautions will be taken by all those involved to maintain 
your confidentiality, only members of the research team given permission by the data custodian will 
have access to your personal data. 
 
In accordance with the University of Nottingham’s, the Government’s and our funders’ policies we 
may share our research data with researchers in other Universities and organisations, including 
those in other countries, for research in health and social care. Sharing research data is important to 
allow peer scrutiny, re-use (and therefore avoiding duplication of research) and to understand the 
bigger picture in particular areas of research. Data sharing in this way is usually anonymised (so 
that you could not be identified) but if we need to share identifiable information we will seek your 
consent for this and ensure it is secure. You will be made aware then if the data is to be shared with 
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countries whose data protection laws differ to those of the UK and how we will protect your 
confidentiality. 
 
Although what you say to us is confidential, should you disclose anything to us which we feel puts 
you or anyone else at any risk, we may feel it necessary to report this to the appropriate persons.  
 
What will happen if I don’t want to carry on with the study?  
Your participation is voluntary and you are free to withdraw at any time, without giving any reason, 
and without your legal rights being affected. If you withdraw we will no longer collect any 
information about you or from you. We will keep the information about you that we have already 
obtained as we are not allowed to tamper with study records and this information may have already 
been used in some analyses and may still be used in the final study analyses.  
Involvement of the General Practitioner/Family doctor (GP)  
If you are enrolled in the study we will inform your General Practitioner. 
 
What will happen to any samples I give? 
The samples will be stored with a code unique to you and securely at the University of Nottingham 
and at The Oxford Haemophilia and Thrombosis Centre under the University’s Human Tissue 
Research Licence (no 12265). At the end of the study samples will be destroyed in accordance with 
the Human Tissue Act guidelines. 
Will any genetic tests be done? 
No, we will not be collecting any genetic samples.  
What will happen to the results of the research study? 
The results of the research may be published. If so, this will be in a medical journal. You will not be 
identified in any report. 
 
Who is organising and funding the research? 
This research is being organised by the University of Nottingham and is being funded by NIHR RfPB. 
 
Who has reviewed the study? 
All research in healthcare is looked at by independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable opinion by 
the local Ethics Committee [ NHS HRA East Midlands – Nottingham 2] 
 
 
Who should be contacted if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers 
who will do their best to answer your questions.  The researchers’ contact details are given at the 
end of this information sheet. If you remain unhappy and wish to complain formally, you can do this 
by contacting the [please provide below the contact details of PALS for the local hospital] 
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In the event that something does go wrong and you are harmed during the research and this is due 
to someone's negligence then you may have grounds for a legal action for compensation against the 
University of Nottingham but you may have to pay your legal costs. The normal National Health 
Service complaints mechanisms will still be available to you. 
 
 
Further information and contact details 
Trial / Study Coordinating Centre: 
Division of Clinical Neuroscience, Stroke 
University of Nottingham 
Hucknall Road 
Nottingham 
NG5 1PB 
Phone: 0115 8231770 
Chief Investigator: 
Prof Nikola Sprigg 
Phone:0115 8231765 
 
Contact details of PALS for the local hospital: 
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DASH: Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage 
 
IRAS Project ID: 233744   CTA ref: 03057/0070/001-0001 
 
Name of Researcher: ___________________________________________ 
 
Name of Participant:  ___________________________________________ 
 
I confirm that I have been given a copy of the Patient Information Sheet (Version 2.0 dated 11 Jan 2019) 
and I agree that I /my relative or friend / this stroke patient (delete as appropriate)  
 
• Will take part in the DASH study 
• For my medical records to be accessed, blood samples to be taken and stored and brain scans 
used by the study team 
• To be followed up at 3 months  
• For my GP to be informed 
• For my contact details to be collected and used for the purpose of the study 
• For my confidential data to be used in further research analysis about ICH.  
 
I understand that I am free to withdraw from the study at any point without giving a reason. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient consent – to be completed if participant has capacity to consent 
 
______________________ ______________      ____________________ 
Name of Participant   Date           Signature 
 
________________________ ______________      ____________________ 
Name of Person taking consent  Date           Signature 
 
________________________ ______________      ____________________ 
Name of Witness if participant  Date           Signature 
unable to physically sign 
Personal or professional nominee consent - to be completed if participant does 
not have capacity to consent 
 
________________________ ______________      ____________________ 
Name of Person giving    Date    Signature 
nominee consent    
 
 
Relationship to patient (please tick):   Relative/carer/friend        Healthcare Professional 
 
______________________ ______________      ____________________ 
Name of Person taking consent  Date    Signature   
 
 
Telemedicine used (please tick if Yes)    
 
________________________ ______________      ____________________ 
Name of Witness if consent taken Date    Signature 
over the telephone     
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